Internal restructuring
Location of affected unit(s)
Within Europe, plants in Germany and the Netherlands are affected. Infomation on plants in other European countries wll follow.
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations

3,000 jobs
Number of planned job losses
Job loss
Announcement Date
21 September 2010
Employment effect (start)
Foreseen end date
30 September 2012


The pharmaceutical company Abbott Laboratories intends to reduce its global workforce by 3,000, with most of the jobs losses due to take place across Europe. The company has already announced 500 job losses at its factory in Weesp (Netherlands) and 300 jobs in Hannover (Germany) with more European job reductions yet to be announced.

Most of the jobs losses will occur in the units previously owned by the pharmaceutical division of Solvay, acquired by Abbott. Following this take-over Abbott is now streamlining its operations and this includes job reductions in divisions such as marketing, R&D, sales and production.

The restructuring plan includes the closure of a Solvay facility in Marietta, Georgia (USA), by the end of 2011, Ms. Brotz said.

In addition, the work force at Solvay sites in Hannover, Germany, and Weesp, the Netherlands, will be scaled back.



Eurofound (2010), Abbott Laboratories, Internal restructuring in World, factsheet number 70953, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/70953.